Skip to main content
2023 Guide to Patient Support Services

Spectrum Pharmaceuticals

2023 PSS Guide

Spectrum Pharmaceutical’s Access4Me


Spectrum Pharmaceuticals offers the Access4Me program to provide access and reimbursement support to patients who have been prescribed Rolvedon (Table).


Access4Me offers a comprehensive list of programs such as the Rolvedon Copay Assistance Program, the Rolvedon Patient Assistance Program, and the First-Cycle Patient Support Program.

Rolvedon Copay Assistance Program

The Rolvedon Copay Assistance Program may reduce out-of-pocket costs for patients with commercial insurance to as little as $0, up to a maximum annual benefit of $15,000 per 12-month enrollment period. Patients may be eligible if they:

  • Have commercial or private insurance that covers Rolvedon
  • Have a copay for Rolvedon
  • Are not participating in Medicare, Medicaid, Medigap, Veterans Affairs, Department of Defense, TRICARE, or other similar federal or state programs
  • Are a resident of the United States.

Rolvedon Patient Assistance Program

Patients who are uninsured or underinsured may be eligible to receive Rolvedon at no cost through the Patient Assistance Program. Patients may be eligible if they:

  • Are uninsured or underinsured for Rolvedon
  • Are a resident of the United States
  • Demonstrate financial need
  • Have an annual income of <500% of the federal poverty level adjusted for family size.

First-Cycle Patient Support Program

New patients can receive their first-cycle dose of Rolvedon free of charge. When enrolling the patient, simply check First-Cycle Patient Support on the enrollment form. Access4Me will conduct the benefits investigation, communicate the results to your office, and confirm patient eligibility for the free dose. This program is limited to one free dose per patient. Patients may be eligible if they:

  • Are a new patient, enrolled in Access4Me
  • Are a resident of the United States.

To enroll your patient in the Access4Me program, visit the Access4Me website.

TABLE Spectrum Oncology Supportive Drug

Patient support program

Rolvedon (eflapegrastim-xnst) injection
To decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with clinically significant incidence of febrile neutropenia
Patient support program

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"